Clinical Trials Directory

Trials / Terminated

TerminatedNCT01129232

Diabetes Virus Detection Project, Intervention With GAD-alum

A Phase II-study (Therapeutic Exploratory) of GAD-alum in Newly Diagnosed Type-1 Diabetic Patients, With Focus One the Presence of Viruses at the Time of Diagnosis

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
6 (actual)
Sponsor
Oslo University Hospital · Academic / Other
Sex
All
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

The purposes of this study are to test whether GAD vaccination can stop the progression of newly diagnosed type 1 diabetes, to describe the related immunological processes (insulitis) in pancreas and small intestines evolving the mechanism of the effect of GAD vaccination and finally try to detect viruses and virus receptors directly in the insulin producing beta cells of the pancreas in patients with newly diagnosed type-1 diabetes mellitus (T1D).

Detailed description

The aetiology of type 1 diabetes is unknown. Both genetic and environmental factors seem to be important for the destruction of insulin producing beta cells in the pancreas. Increasing indirect evidences exist that picornaviruses may either directly or indirectly through autoimmune processes destroy beta cells. New sensitive assays have been developed to detect these viruses and to study the immunological processes, especially T-cell function. Microsurgical technology has been refined, now making pancreatic biopsies a safe procedure. This study focuses on advanced in depth studies of immunology and virology in pancreatic tissue and small intestine at an early stage of disease.

Conditions

Interventions

TypeNameDescription
DRUGGAD-alum20 µg of GAD-alum injected sc after the biopsy, and repeated after one month
OTHERPlaceboPlacebo injected after the biopsy and repeated after one month (similar to the GAD-alum-arm)

Timeline

Start date
2011-01-01
Primary completion
2013-01-01
Completion
2013-01-01
First posted
2010-05-24
Last updated
2018-05-17

Locations

1 site across 1 country: Norway

Source: ClinicalTrials.gov record NCT01129232. Inclusion in this directory is not an endorsement.